Skip to main content
. 2020 Oct 14;156(12):1–10. doi: 10.1001/jamadermatol.2020.3617

Figure 2. Psoriasis Symptom Scale (PSS) Items Scales Responder Analyses (Exploratory Outcomes)a.

Figure 2.

A, PSS pain. B, PSS redness. C, PSS itchiness. D, PSS burning.

aSignificantly greater proportions of patients treated with risankizumab achieved a score of 0 or 1 on each of the PSS items at week 4 through week 16 compared with placebo. Compared with patients treated with ustekinumab, a significantly greater proportion of those treated with risankizumab achieved PSS pain = 0 (P < .001 from week 22 onward), PSS redness = 0 (P = .01 at week 4, P = .001 at week 8, P = .001 at week 12, and P < .001 at all other time points, PSS itchiness = 0 (P < .001 from week 16 onward), and PSS burning = 0 (P < .001 from week 28 onward).